Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
By C. Fuchs, J. Marshall, E. Mitchell, R. Wierzbicki, V. Ganju, M. Jeffery, J. Schulz, D. Richards, Raoudha Soufi-Mahjoubi, Benjamin Wang and 1 more. Journal of Clinical Oncology, 2007
874 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/56e31b078f53755060a3e724c146171fd462fb10
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, neutral): “The TRI‑ COLORE trial, a phase III trial conducted in Japan, compared the efficacy and safety of S‑1 + IRI + BEV with FOLFOX + BEV or CAPOX + BEV as first‑line therapy for PS 0–1 patients with unresectable colorectal cancer.”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Capecitabine is less frequently used in combination with irinotecan due to early concerns that it was more toxic than FOLFIRI [240, 241].”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (2011, neutral): “(2) FOLFIRI(6) [34, 35] ± bevacizumab [36, 37] (3) FOLFOX ± cetuximab/panitumumab [38, 39] (4) FOLFIRI ± cetuximab/panitumumab [40, 41] (5) 5-FU ? LV [42] ± bevacizumab [43, 44] or UFT ? LV [45] FOLFIRI bevacizumab* or CPT-11”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015, neutral): “• FOLFOX note 1 [57, 58] +Bmab [54] • CapeOX note 2 + Bmab [59, 60] • FOLFIRI note 3 [61, 62] +Bmab [63, 64] • FOLFOX + Cmab/Pmab [65, 66] • FOLFIRI + Cmab/Pmab [67, 68] • FOLFOXIRI note 4 [69] • Infusional 5-FU + l-LV [70, 71] +Bmab [72, 73] • Cape [74, 75] + Bmab [76] • UFT + LV [77–79]”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient ”